Evidence map›Paper›PMID 23532363›Full record

Trial reportJournal of thrombosis and thrombolysis2014

Elevated lipoprotein(a) levels and homozygous human platelet antigen 1b (HPA-1b) genotype are risk factors for intrauterine growth restriction (IUGR).

Andrea Gerhardt, Nadja Howe, Jan Steffen Krüssel, Ruediger Eberhard Scharf, Rainer Bernd Zotz

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of thrombosis and thrombolysis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Andrea GerhardtDepartment of Hemostasis and Transfusion Medicine, Heinrich Heine University Medical Center, Moorenstrasse 5, 40225, Düsseldorf, Germany, gerhardt@blutgerinnung-ulm.de.
Nadja Howe
Jan Steffen Krüssel
Ruediger Eberhard Scharf
Rainer Bernd Zotz
Heinrich Heine University Düsseldorf · DEDüsseldorf University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The risk of premature manifestation of cardiovascular disease is higher in women after a maternal placental syndrome, especially with a history of fetal IUGR. Aim of the study was to assess hereditary risk factors for arterial thrombosis as risk factors for IUGR. 183 women with fetal IUGR birth weight below the 10th percentile for gestational age and 300 control women were evaluated using a case-control design. In 121 of the 183 women, the newborns' birth weight was below the 5th percentile for gestational age. A risk association could be shown for homozygous human platelet antigen 1b genotype (OR 3.2, P = 0.038) in women with a history for a newborn's birth weight below the 5th percentile. Elevated levels of lipoprotein(a) (>0.7 g/l [95 % percentile], OR 2.9, P = 0.048) also represent a risk association in the same group of subjects. So did elevated levels of lipoprotein(a) (>0.7 g/l [95 % percentile], OR 3.4, P = 0.015) in women with a history for a newborn's birth weight below the 10th percentile. Risk factors of arterial thrombosis such as platelet receptor genotypes associated with platelet thrombogenicity and elevated levels of lipoprotein(a) might be of importance in the pathogenesis of IUGR.

Indexed as

HomozygoteAdultAntigens, Human PlateletFemaleFetal Growth RetardationHumansLipoproteinsRetrospective StudiesRisk FactorsThrombosisAntigens, Human Platelethuman platelet antigen 1bLipoproteins

Identifiers

PMID23532363
OpenAlexW2000485898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.